Abstract Details

Females were younger at first migraine episode (22.7 vs. 29.1 years) and diagnosis (26.1 vs. 32.0 years) than males; Caucasians were younger than minorities at both events. More males are managed by migraine specialists (52% vs. 36%), especially minority males (56%) versus white females (35%). Minorities, especially minority females, were more likely covered by Medicaid (15% vs. 7%). More females were diagnosed with chronic migraine (41% vs. 24%), while more males were diagnosed with low frequency episodic migraine (28% vs. 16%). Comorbid hypertension was more common among males (21% vs. 13%) and minorities (21% vs. 13%), with highest rates among Caucasian males (23%) and minority females (24%). Females were more often diagnosed with anxiety (17% vs. 8%) and depression (27% vs. 21%).

Whereas 68% of females had previously failed ≥2 previous preventive therapies, 51% of males had failed one preventive therapy and were more likely to have recently been prescribed fremanezumab (22% vs. 17%) or eptinezumab (9% vs. 5%). Patient request (32% vs. 24%), efficacy onset speed expectation (29% vs. 22%), family planning consideration (12% vs. 3%), and non-adherence concern (11% vs. 5%) more often influenced therapy selection among minority patients.